ReCellTis Wound Care is a proprietary topical wound cream to treat acute & chronic wounds such as diabetic wounds, pressure ulcers (bed sores), post-surgical wounds, and most open wounds from Stage 1 to Stage 4 with proven effectiveness.
I had a skin infection with ulcers that would not go away. After I tried receltis it all went away. I’m really impressed that something like this can really make a difference.
I was skeptical that this product would close the wound that I have on my hand. I was very skeptical at first but decided to give it a try. To my surprise, it worked!! 5 days later my wound was closed!
This is an amazing product! It does what it says. Great work.
Traditional wound care formulations either contain one antibiotic to kill or inhibit microbes or an enzyme to chew off old tissue. ReCellTis™ and its proprietary formulation provide numerous benefits besides killing microbes. ReCellTis™ contains 4 antibiotics with boosted antibacterial efficiency (Zinc, Silver), thus providing much broader anti-microbial spectrum coverage along with antifungal properties.
ReCellTis™ Wound Care helps kill infectious microbes with a proprietary formula including broad spectrum antibiotics, it also promotes tissue repair by boosting the body’s immune system, stimulating skin cell production, and providing energy to the regenerating skin and underlying tissues.
ReCellTis not only kills the infectious microbes with broad spectrum antibiotics, it also promotes tissue repair by boosting the body’s immune system, stimulating skin cell production, and providing energy to the regenerating skin and underlying tissues.
ReCellTis has successfully healed wounds on patients facing amputation, therefore avoiding the trauma of losing a limb.
Because every insurance carrier is different, you’ll need to consult your insurance carrier. ReCellTis is made affordable for those who do not have insurance or if your insurance carrier does not accept to pay for ReCellTis.
No, ReCellTis is FDA-approved for OTC sales.
Thus far, no side effects have been reported by using ReCellTis.